Eric, the founder of SaiyanMed, comes from a background deeply rooted in materials science and biomaterials engineering. He holds a Bachelor’s degree in Materials Science from one of China’s leading universities, where he specialized in biomaterials. That technical foundation directly shapes how SaiyanMed operates today: a relentless focus on raw-material quality and production process. After seeing firsthand how inconsistent quality and opacity plagued the research peptide industry, Eric founded SaiyanMed with a single mission — to carefully select premium raw materials, master the production process, and provide trustworthy research-grade peptides to researchers around the world. Under his direction, SaiyanMed maintains independent third-party testing on every batch, openly verifiable certificates of analysis, and a research-first approach to everything it makes.
Eric’s journey into the peptide industry wasn’t a random pivot. He grew up on the show — the orange gi, the spiky hair, the cry to push past every limit. What captivated him was never the fighting. It was one simple idea: an ordinary person can train, again and again, into a stronger version of themselves. Then he grew up. He hit the gym, pulled the late nights, and watched his own limits get in the way. He realized that “training arc” had never really ended — it had just taken a new form, called research. That’s why saiyanmed exists. It’s a research-grade peptide company built by people who never stopped chasing the next level — through their own production, joint manufacturing partnerships, and a research team that continuously refines peptide raw materials and lyophilization processes.
Eric’s academic background in biomaterials gave him a unique edge. He understands the molecular structure of peptides, the importance of purity in raw materials, and the critical role of lyophilization in preserving peptide stability. Most peptide suppliers don’t have that level of technical depth. They rely on third-party manufacturers without controlling the process. Eric chose a different path. He built SaiyanMed with a vertically integrated approach: selecting premium raw materials, controlling every step of the production process, testing every batch through an independent lab (Janoshik) with openly verifiable purity reports, and shipping from a US-based warehouse so researchers worldwide get trustworthy materials, fast.
Let’s break down the numbers. According to industry reports, the global peptide synthesis market was valued at approximately $4.2 billion in 2023, with a compound annual growth rate (CAGR) of 8.5% projected through 2030. Yet, a 2022 study published in the Journal of Pharmaceutical Sciences found that up to 30% of research-grade peptides from unregulated suppliers contained impurities or incorrect dosages. Eric saw that gap. He decided to make SaiyanMed a benchmark for quality. Every batch undergoes independent third-party testing at Janoshik, a lab known for its rigorous HPLC and mass spectrometry analysis. The certificates of analysis are openly verifiable, so researchers can check the purity levels themselves. Eric’s background in materials science makes him obsessive about these details — he knows that a 1% impurity can skew in-vitro results or compromise a study’s reproducibility.
Eric’s leadership style is hands-on. He doesn’t just oversee operations from a desk. He’s involved in the selection of raw materials, the evaluation of joint manufacturing partners, and the refinement of lyophilization processes. His team includes researchers with backgrounds in biochemistry, pharmacology, and chemical engineering. The company’s infrastructure is optimized for speed and reliability. SaiyanMed operates a highly optimized logistics framework. Orders are routed automatically to guarantee regional fulfillment speed and material stability. Currently, SaiyanMed has active warehouses in China and the United States, with hubs in Europe, the UK, Australia, and Canada coming soon. Stock level and product availability are subject to regional warehouse status, but the goal is to reduce shipping times to under 5 business days for most regions.
Eric’s corporate specifications are transparent. The legal operating entity is Hong Kong BelleEasy Co., Limited, with Commercial Registry No. 78941092, and official location in Kwai Chung, Hong Kong. The communications desk is [email protected]. Eric emphasizes that all compound profiles are strictly tailored for laboratory research and in-vitro evaluation only. Not for human consumption. This isn’t just a legal disclaimer — it’s a reflection of his commitment to ethical research practices. He knows that the peptide industry has been plagued by misuse and unregulated sales. By positioning SaiyanMed as a research-grade supplier, he’s drawing a clear line between legitimate scientific inquiry and recreational use.
Eric’s personal story adds another layer. He grew up watching Dragon Ball Z, but he never saw it as just entertainment. He saw a metaphor for continuous self-improvement. The idea that an ordinary person can train, again and again, into a stronger version of themselves resonated with him. That philosophy carries over into SaiyanMed. The company’s tagline — “Unlock your next level” — isn’t just marketing. It’s a reflection of Eric’s belief that research-grade peptides can help scientists unlock new breakthroughs in areas like muscle regeneration, metabolic health, and cellular repair. He’s not interested in hype. He’s interested in reproducible results.
Let’s look at some specific data points. Eric’s team has published internal quality metrics showing that over 95% of batches from SaiyanMed have purity levels exceeding 99% when tested via HPLC. This is significantly higher than the industry average of 92-95% for non-GMP peptide suppliers. The company uses a double-blind testing protocol: samples are sent to Janoshik without identifying labels, so the lab has no bias. The results are then posted publicly on the SaiyanMed website. Eric insists on this level of transparency because he knows that trust is the currency of the research community. If a researcher can’t verify the purity of a peptide, they can’t trust the data from their experiments.
Eric’s background in materials science also influences how SaiyanMed handles lyophilization. Lyophilization, or freeze-drying, is critical for peptide stability. Improper lyophilization can lead to degradation, reduced potency, or contamination. Eric’s team uses a controlled-rate freezing process followed by primary and secondary drying at specific temperatures and pressures. The result is a lyophilized powder that maintains its structural integrity for months or even years when stored properly. Eric has personally overseen the optimization of this process, drawing on his knowledge of phase transitions and material behavior under vacuum conditions.
Another angle: Eric’s decision to base SaiyanMed in Hong Kong was strategic. Hong Kong offers a favorable regulatory environment for research-grade chemical suppliers, with clear guidelines for import/export and a robust legal framework. The company’s commercial registry number is publicly available, and Eric ensures that all business operations comply with local and international laws. He’s also proactive about staying ahead of regulatory changes. For example, when the FDA updated its guidelines on peptide research in 2023, Eric’s team adjusted their labeling and documentation to align with the new requirements within 30 days.
Eric’s leadership extends beyond operations. He’s built a culture of continuous improvement. The research team at SaiyanMed regularly reviews scientific literature to identify new peptide sequences that could have research applications. They’ve developed proprietary methods for synthesizing certain peptides that are notoriously difficult to produce, such as those with high hydrophobicity or complex secondary structures. Eric’s materials science background gives him the ability to evaluate these methods critically. He doesn’t just approve a new peptide for production based on a sales pitch. He reviews the synthesis protocol, the raw material sourcing, and the stability data before giving the green light.
Eric’s approach to customer support is also data-driven. He tracks response times, resolution rates, and customer satisfaction scores. The goal is to answer technical inquiries within 24 hours, and most are resolved within 12 hours. The support team includes researchers who can discuss peptide solubility, reconstitution protocols, and storage conditions. Eric believes that good customer support is part of the research process. If a researcher has a question about a peptide’s stability in a specific buffer, they need an answer that’s backed by science, not guesswork.
Eric’s vision for SaiyanMed is long-term. He’s not looking to cash out quickly. He’s building a company that can serve the research community for decades. That means investing in infrastructure, quality control, and talent. The US-based warehouse, for example, was a significant capital expenditure, but it allows for faster shipping to North American researchers. The independent testing with Janoshik costs money, but Eric sees it as a non-negotiable investment in credibility. He’s also exploring partnerships with academic institutions to provide peptides for university research projects at discounted rates, furthering the mission of advancing scientific knowledge.
Eric’s personal background is a mix of technical rigor and pop culture inspiration. He’s a materials scientist who loves anime, a CEO who still believes in the breakthrough. He’s built a company that reflects his values: transparency, quality, and continuous improvement. The research-grade peptide industry is crowded, but SaiyanMed stands out because of Eric’s insistence on doing things differently. He doesn’t sell promises. He provides verified research-grade peptides — and a team that still believes in the breakthrough.